ASCO: Sanofi says early amcenestrant data could see it be 'endocrine backbone therapy' in breast cancer

A new early peek at data from Sanofi’s breast cancer hopeful amcenestrant has encouraged the French Big Pharma to see it placed firmly at the front of future treatment pathways.